Milestone Pharmaceuticals enrolled the first patient in its Phase 3 ReVeRA-301 pivotal trial. The study evaluates etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).
Researchers are testing the same 70 mg repeat-dose regimen currently FDA-approved for paroxysmal supraventricular tachycardia (PSVT). This product is marketed under the brand name CARDAMYST.
Milestone shares (NASDAQ: MIST) rose 3.9% following the announcement. The trial aims to establish a self-administered treatment option to reduce the frequency of emergency medical interventions for AFib-RVR patients.